Barcelona, Spain

Carmen Almansa Rosales

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 102(Granted Patents)


Company Filing History:


Years Active: 2004-2013

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Carmen Almansa Rosales: Innovator in Kinase Inhibitors

Introduction

Carmen Almansa Rosales is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. With a total of 8 patents to his name, his work has garnered attention in the pharmaceutical industry.

Latest Patents

Carmen's latest patents include innovative compounds that serve as p38 kinase inhibitors. One of his notable inventions is the Pyrazolopyridine derivatives, which are new compounds of formula (I) and their salts, useful in inhibiting p38 kinase. Additionally, he has developed N-containing heteroaryl derivatives that act as JAK3 kinase inhibitors. These compounds, represented by formulas I or II, are designed to target JAK, particularly JAK3, kinase, showcasing his expertise in this area.

Career Highlights

Throughout his career, Carmen has worked with reputable companies such as Palau Pharma and J. Uriach & Cia. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical sector.

Collaborations

Carmen has collaborated with several talented individuals, including Marina Virgili Bernadó and Concepción González González. These partnerships have played a crucial role in advancing his research and patent development.

Conclusion

Carmen Almansa Rosales is a distinguished inventor whose work in kinase inhibitors has made a significant impact in the field of medicinal chemistry. His innovative patents and collaborations highlight his dedication to advancing pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…